United Kingdom - English - VMD (Veterinary Medicines Directorate)

complements of scotland ltd (trading as freeman's homeopathic pharmacy) - nux vomica (homeopathic dilution of) - tablet - n/a (homeopathic authorisation) - all species

United States - English - NLM (National Library of Medicine)

washington homeopathic products - nux vomica 200c - to relieve the symptoms of vomiting. indications: nux vomica vomiting if symptoms persist/worsen or if pregnant/nursing, stop use and consult your practitioner.

United States - English - NLM (National Library of Medicine)

washington homeopathic products - nux vomica 30c - to relieve the symptoms of vomiting. indications: nux vomica vomiting if symptoms persist/worsen or if pregnant/nursing, stop use and consult your practitioner.

United States - English - NLM (National Library of Medicine)

indiana botanic gardens - strychnos nux-vomica seed (unii: 269xh13919) (strychnos nux-vomica seed - unii:269xh13919), potassium arsenite anhydrous (unii: bm2u42paki) (potassium cation - unii:295o53k152), berberis vulgaris root bark (unii: 1th8q20j0u) (berberis vulgaris root bark - unii:1th8q20j0u), graphite (unii: 4qqn74lh4o) (graphite - unii:4qqn74lh4o), arsenic trioxide (unii: s7v92p67ho) (arsenic trioxide - unii:s7v92p67ho), calcium sulfide (unii: 1mbw07j51q) (calcium cation - unii:2m83c4r6zb), tetraarsenic tetrasulfide - strychnos nux-vomica seed 12 [hp_x] - for the relief of itching, burning and scaly conditions not due to insect or allergy conditions for the relief of itching, burning and scaly conditions not due to insect or allergy conditions for your protection, this container has an outer safety seal. (do not accept if missing or broken.) best if used by date on bottle. store in a dry cool place. any questions? 1-800-644-8327 website: www.botanicchoice.com

United States - English - NLM (National Library of Medicine)

washington homeopathic products - nux vom - to relieve the symptoms of vomiting. indications: nux vom   vomiting if symptoms persist/worsen or if pregnant/nursing, stop use and consult your practitioner.

United States - English - NLM (National Library of Medicine)

washington homeopathic products - nux vom - to relieve the symptoms of vomiting. indications:  nux vom   vomiting if symptoms persist/worsen or if pregnant/nursing, consult your practitioner.

United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories limited - fondaparinux sodium (unii: x0q6n9usoz) (fondaparinux - unii:j177fow5jl) - fondaparinux sodium 2.5 mg in 0.5 ml - fondaparinux sodium injection is indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe): - in patients undergoing hip fracture surgery, including extended prophylaxis; - in patients undergoing hip replacement surgery; - in patients undergoing knee replacement surgery; - in patients undergoing abdominal surgery who are at risk for thromboembolic complications. fondaparinux sodium injection is indicated for the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium. fondaparinux sodium injection is indicated for the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital. fondaparinux sodium injection is contraindicated in the following conditions: - severe renal impairment (creatinine clearance [crcl] <30 ml/min). [see warnings and precautions (5.3) and use in specific populations (8.6)] - active major bleeding. - bacterial endocarditi

United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories inc. - fondaparinux sodium (unii: x0q6n9usoz) (fondaparinux - unii:j177fow5jl) - fondaparinux sodium 2.5 mg in 0.5 ml - fondaparinux sodium injection is indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe): - in patients undergoing hip fracture surgery, including extended prophylaxis; - in patients undergoing hip replacement surgery; - in patients undergoing knee replacement surgery; - in patients undergoing abdominal surgery who are at risk for thromboembolic complications. fondaparinux sodium injection is indicated for the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium. fondaparinux sodium injection is indicated for the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital. fondaparinux sodium injection is contraindicated in the following conditions: - severe renal impairment (creatinine clearance [crcl] <30 ml/min). [see warnings and precautions (5.3) and use in specific populations (8.6)] - active major bleeding. - bacterial endocarditis

United States - English - NLM (National Library of Medicine)

eugia us llc - fondaparinux sodium (unii: x0q6n9usoz) (fondaparinux - unii:j177fow5jl) - fondaparinux sodium 2.5 mg in 0.5 ml - fondaparinux sodium injection is indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe): - in patients undergoing hip fracture surgery, including extended prophylaxis; - in patients undergoing hip replacement surgery; - in patients undergoing knee replacement surgery; - in patients undergoing abdominal surgery who are at risk for thromboembolic complications. fondaparinux sodium injection is indicated for the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium. fondaparinux sodium injection is indicated for the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital. fondaparinux sodium injection is contraindicated in the following conditions: - severe renal impairment (creatinine clearance [crcl] <30 ml/min) [ see  warnings and precautions (5.3) and use in specific populations (8.6) ]. - active major bleeding. - bacterial endocarditis. - thrombocytopenia associated with a positive in vitro test for anti-platelet antibody in the presence of fondaparinux sodium. - body weight <50 kg (venous thromboembolism [vte] prophylaxis only) [see warnings and precautions (5.4) ]. - history of serious hypersensitivity reaction (e.g., angioedema, anaphylactoid/anaphylactic reactions) to fondaparinux sodium. risk summary available data from published literature and postmarketing reports have not reported a clear association with fondaparinux sodium and adverse developmental outcomes. fondaparinux sodium plasma concentrations obtained from four women treated with fondaparinux sodium during pregnancy and their newborn infants demonstrated low placental transfer of fondaparinux sodium (see data). there are risks to the mother associated with untreated venous thromboembolism in pregnancy and a risk of hemorrhage in the mother and fetus associated with use of anticoagulants (see clinical considerations). in animal reproduction studies, there was no evidence of adverse developmental outcomes when fondaparinux sodium was administered to pregnant rats and rabbits during organogenesis at doses 32 and 65 times, respectively, the recommended human dose based on body surface area. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk pregnancy confers an increased risk for thromboembolism that is higher for women with underlying thromboembolic disease and certain high-risk pregnancy conditions. published data describe that women with a previous history of venous thrombosis are at high risk for recurrence during pregnancy. fetal/neonatal adverse reactions fondaparinux sodium has been demonstrated to cross the placenta in humans (see data). use of anticoagulants, including fondaparinux sodium, may increase the risk of bleeding in the fetus and neonate. monitor neonates for bleeding [see warnings and precautions (5.2, 5.4, 5.6)]. labor or delivery all patients receiving anticoagulants, including pregnant women, are at risk for bleeding. fondaparinux sodium use during labor or delivery in women who are receiving neuraxial anesthesia may result in epidural or spinal hematomas. pregnant women receiving fondaparinux sodium should be carefully monitored for evidence of bleeding or unexpected changes in coagulation parameters. consideration for use of a shorter acting anticoagulant should be specifically addressed as delivery approaches [see warnings and precautions (5.1, 5.6)]. data human data in a study of five pregnant women treated with fondaparinux sodium during the third trimester of pregnancy at a dose of 2.5 mg/day, four of the women had elevated anti-factor xa activity noted in the cord blood. anti-factor xa clotting times in these four cases were between 37.5 and 50.9 seconds. the patient who did not have elevated anti-factor xa activity had received only one dose of fondaparinux sodium 22 hours prior to delivery. the concentration of fondaparinux sodium in umbilical cord plasma was approximately 1/10th the level of fondaparinux sodium in maternal plasma. none of the infants experienced adverse effects. animal data embryo-fetal development studies have been conducted with fondaparinux sodium in pregnant rats at subcutaneous doses up to 10 mg/kg/day (about 32 times the recommended human dose based on body surface area) administered from days 6 to 17 of gestation and pregnant rabbits at subcutaneous doses up to 10 mg/kg/day (about 65 times the recommended human dose based on body surface area) administered from days 6 to 18 of gestation. these studies have revealed no evidence of adverse developmental outcomes when fondaparinux sodium was administered to pregnant rats and rabbits during organogenesis. additionally, there were no effects on pre and postnatal development in a study conducted in rats at subcutaneous doses up to 10 mg/kg/day (about 32 times the recommended human dose based on body surface area). risk summary there are no data on the presence of fondaparinux sodium in human milk, or the effects on milk production. limited clinical data during lactation preclude a clear determination of the risk of fondaparinux sodium to an infant during lactation; therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for fondaparinux sodium and any potential adverse effects on the breastfed infant from fondaparinux sodium or from the underlying maternal condition. safety and effectiveness of fondaparinux sodium in pediatric patients have not been established. because risk for bleeding during treatment with fondaparinux sodium is increased in adults who weigh <50 kg, bleeding may be a particular safety concern for use of fondaparinux sodium in the pediatric population [see warnings and precautions (5.4)]. in clinical trials the efficacy of fondaparinux sodium in the elderly (65 years or older) was similar to that seen in patients younger than 65 years; however, serious adverse events increased with age. when using fondaparinux sodium in elderly patients, paying particular attention to dosing directions and concomitant medications (especially anti-platelet medication) [see warnings and precautions (5.2)]. fondaparinux sodium is substantially excreted by the kidney, and the risk of adverse reactions to fondaparinux sodium may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, assess renal function prior to fondaparinux sodium administration [see contraindications (4), warnings and precautions (5.3), and clinical pharmacology (12.4)]. in the peri-operative hip fracture, hip replacement, or knee replacement surgery clinical trials with patients receiving fondaparinux sodium 2.5 mg, serious adverse events increased with age for patients receiving fondaparinux sodium. the incidence of major bleeding in clinical trials of fondaparinux sodium by age is provided in table 6. patients with impaired renal function are at increased risk of bleeding due to reduced clearance of fondaparinux sodium [see contraindications (4) and warnings and precautions (5.3)] . assess renal function periodically in patients receiving fondaparinux sodium. discontinue fondaparinux sodium immediately in patients who develop severe renal impairment while on therapy. after discontinuation of fondaparinux sodium, its anticoagulant effects may persist for 2 to 4 days in patients with normal renal function (i.e., at least 3 to 5 half-lives). the anticoagulant effects of fondaparinux sodium may persist even longer in patients with renal impairment [see clinical pharmacology (12.4)]. following a single, subcutaneous dose of 7.5 mg of fondaparinux sodium in patients with moderate hepatic impairment (child-pugh category b) compared to subjects with normal liver function, changes from baseline in aptt, pt/inr, and antithrombin iii were similar in the two groups. however, a higher incidence of hemorrhage was observed in subjects with moderate hepatic impairment than in normal subjects, especially mild hematomas at the blood sampling or injection site. the pharmacokinetics of fondaparinux have not been studied in patients with severe hepatic impairment [see dosage and administration (2.5) and clinical pharmacology (12.4)]. fondaparinux sodium (fon'' da par' in ux soe' dee um) injection, usp for subcutaneous use be sure that you read, understand, and follow the step-by-step instructions for use, before you try to give yourself an injection of fondaparinux sodium for the first time and each time you get a new prescription. there may be new information. talk to your doctor or pharmacist if you have any questions. do not use fondaparinux sodium if: - the solution appears discolored (the solution should normally appear clear) the solution appears discolored (the solution should normally appear clear) -  you see any particles in the solution  you see any particles in the solution -  the syringe is damaged  the syringe is damaged how should i give an injection of fondaparinux sodium? fondaparinux sodium is injected into a skin fold of the lower stomach area (abdomen). do not inject fondaparinux sodium into muscle. usually a doctor or nurse will give this injection to you. in some cases you may be taught how to do this yourself.  - do not touch the needle or let it come in contact with any surface before the injection. a small air bubble in the syringe is normal. - to be sure that you do not lose any medicine from the syringe, do not try to remove air bubbles from the syringe before giving the injection. - put your used fondaparinux sodium needles and syringes in a fda-cleared sharps disposal container right away after use. do not throw away (dispose of) loose needles and syringes in your household trash. - if you do not have a fda-cleared sharps disposal container, you may use a household container that is: made of a heavy-duty plastic, can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out, upright and stable during use, leak-resistant, and properly labeled to warn of hazardous waste inside the container. - made of a heavy-duty plastic, - can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out, - upright and stable during use, - leak-resistant, and - properly labeled to warn of hazardous waste inside the container. - when your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. there may be state or local laws about how you should throw away used needles and syringes. for more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the fda's website at: http://www.fda.gov/safesharpsdisposal. - do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. do not recycle your used sharps disposal container. - the safety system can only be activated once the syringe has been emptied. - activation of the safety system must be done only after removing the needle from the patient’s skin. - do not replace the needle shield after injection. - the safety system should not be sterilized. - activation of the safety system may cause minimal splatter of fluid. for optimal safety activate the system while orienting it downwards away from yourself and others.  this instructions for use has been approved by the u.s. food and drug administration. distributed by: eugia us llc 279 princeton-hightstown rd. e. windsor, nj 08520 manufactured by: eugia pharma specialities limited hyderabad - 500032 india revised: july 2023

United States - English - NLM (National Library of Medicine)

mylan institutional llc - fondaparinux sodium (unii: x0q6n9usoz) (fondaparinux - unii:j177fow5jl) - fondaparinux sodium 2.5 mg in 0.5 ml - fondaparinux sodium injection is indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe): fondaparinux sodium injection is indicated for the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium. fondaparinux sodium injection is indicated for the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital. fondaparinux sodium injection is contraindicated in the following conditions: available data from published literature and postmarketing reports have not reported a clear association with fondaparinux sodium and adverse developmental outcomes. fondaparinux sodium plasma concentrations obtained from four women treated with fondaparinux sodium injection during pregnancy and their newborn infants demonstrated low placental transfer of fondaparinux sodium (see data). there are risks to the mother associated with untreated venous thromboembol